This study provides a reference for the clinical application of ARRB2 as a prognostic biomarker and potential therapeutic target, and we will enrich its mechanism of action in chRCC through more experiments in the future. This evidence concerns the gene ARRB2 and chromophobe renal cell carcinoma.